Veljko Veljkovic

Summary

Publications

  1. pmc Physical activity and natural anti-VIP antibodies: potential role in breast and prostate cancer therapy
    Milena Veljkovic
    Sveti Sava Hospital, Belgrade, Serbia
    PLoS ONE 6:e28304. 2011
  2. ncbi request reprint Simple and general criterion for "in silico" screening of candidate HIV drugs
    Nevena Veljkovic
    Center for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, P O Box 522, 11001 Belgrade, Serbia
    Curr Pharm Biotechnol 14:561-9. 2013
  3. ncbi request reprint The role of long-range intermolecular interactions in discovery of new drugs
    Nevena Veljkovic
    University of Belgrade, Institute of Nuclear Sciences Vinca, Center for Multidisciplinary Research, P O Box 522, 11001 Belgrade, Serbia 381 11 2453 686 381 11 3440 100
    Expert Opin Drug Discov 6:1263-70. 2011
  4. pmc Characterization of conserved properties of hemagglutinin of H5N1 and human influenza viruses: possible consequences for therapy and infection control
    Veljko Veljkovic
    Center for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, P O Box 522, 11001 Belgrade, Serbia
    BMC Struct Biol 9:21. 2009
  5. pmc Identification of hemagglutinin structural domain and polymorphisms which may modulate swine H1N1 interactions with human receptor
    Veljko Veljkovic
    Center for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, PO Box 522, 11001 Belgrade, Serbia
    BMC Struct Biol 9:62. 2009
  6. doi request reprint Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?
    Milena Veljkovic
    Sveti Sava Hospital, Nemanjina 2, 11000 Belgrade, Serbia
    Med Hypotheses 77:404-8. 2011
  7. ncbi request reprint Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease
    Nevena Veljkovic
    Laboratory for Multidisciplinary Research, Institute of Nuclear Sciences, P O Box 522, 11001 Belgrade, Serbia and Montenegro
    J Clin Virol 31:S39-44. 2004
  8. ncbi request reprint Discovery of new therapeutic targets by the informational spectrum method
    Nevena Veljkovic
    Center for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, Belgrade, Serbia
    Curr Protein Pept Sci 9:493-506. 2008
  9. doi request reprint AIDS vaccine: efficacy, safety and ethics
    Veljko Veljkovic
    Center for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, 11001 Belgrade, Serbia
    Vaccine 26:3072-7. 2008
  10. ncbi request reprint Recombination property of the HIV-1 gp120 gene
    Jelena Prljic
    Center for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, Belgrade, Yugoslavia
    Int Rev Immunol 23:447-54. 2004

Collaborators

Detail Information

Publications19

  1. pmc Physical activity and natural anti-VIP antibodies: potential role in breast and prostate cancer therapy
    Milena Veljkovic
    Sveti Sava Hospital, Belgrade, Serbia
    PLoS ONE 6:e28304. 2011
    ....
  2. ncbi request reprint Simple and general criterion for "in silico" screening of candidate HIV drugs
    Nevena Veljkovic
    Center for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, P O Box 522, 11001 Belgrade, Serbia
    Curr Pharm Biotechnol 14:561-9. 2013
    ....
  3. ncbi request reprint The role of long-range intermolecular interactions in discovery of new drugs
    Nevena Veljkovic
    University of Belgrade, Institute of Nuclear Sciences Vinca, Center for Multidisciplinary Research, P O Box 522, 11001 Belgrade, Serbia 381 11 2453 686 381 11 3440 100
    Expert Opin Drug Discov 6:1263-70. 2011
    ..The addition of the computer-aided design techniques based on the EIIP/AQVN concept to the research and development will lead not only to a significant reduction in cost but also to an acceleration in the development of new drugs...
  4. pmc Characterization of conserved properties of hemagglutinin of H5N1 and human influenza viruses: possible consequences for therapy and infection control
    Veljko Veljkovic
    Center for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, P O Box 522, 11001 Belgrade, Serbia
    BMC Struct Biol 9:21. 2009
    ..Here we compare informational and structural properties of the hemagglutinin (HA) of H5N1 virus and human influenza virus subtypes, which are important for the receptor/virus interaction...
  5. pmc Identification of hemagglutinin structural domain and polymorphisms which may modulate swine H1N1 interactions with human receptor
    Veljko Veljkovic
    Center for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, PO Box 522, 11001 Belgrade, Serbia
    BMC Struct Biol 9:62. 2009
    ..Here we have studied properties of hemagglutinin of A/H1N1 which may modulate virus/receptor interaction...
  6. doi request reprint Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?
    Milena Veljkovic
    Sveti Sava Hospital, Nemanjina 2, 11000 Belgrade, Serbia
    Med Hypotheses 77:404-8. 2011
    ..The molecular mechanisms underlying the phenomenon of suppression of breast cancer in the HIV-infected population may serve as a basis for development of a new platform for prevention and treatment of breast cancer...
  7. ncbi request reprint Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease
    Nevena Veljkovic
    Laboratory for Multidisciplinary Research, Institute of Nuclear Sciences, P O Box 522, 11001 Belgrade, Serbia and Montenegro
    J Clin Virol 31:S39-44. 2004
    ..Based on these findings we proposed the anti-NTM antibodies as useful prognostic marker for HIV disease...
  8. ncbi request reprint Discovery of new therapeutic targets by the informational spectrum method
    Nevena Veljkovic
    Center for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, Belgrade, Serbia
    Curr Protein Pept Sci 9:493-506. 2008
    ....
  9. doi request reprint AIDS vaccine: efficacy, safety and ethics
    Veljko Veljkovic
    Center for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, 11001 Belgrade, Serbia
    Vaccine 26:3072-7. 2008
    ..We comment on the efficacy, safety and ethics of AIDS vaccine, and the urgent need for a new strategy for AIDS vaccine development...
  10. ncbi request reprint Recombination property of the HIV-1 gp120 gene
    Jelena Prljic
    Center for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, Belgrade, Yugoslavia
    Int Rev Immunol 23:447-54. 2004
    ....
  11. pmc Novel phylogenetic algorithm to monitor human tropism in Egyptian H5N1-HPAIV reveals evolution toward efficient human-to-human transmission
    Vladimir R Perovic
    Center for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, University of Belgrade, Belgrade, Serbia
    PLoS ONE 8:e61572. 2013
    ..The extensive evolution of Egyptian H5N1-HPAIV towards a preferential human tropism underlines an urgent need to closely monitor these viruses with respect to molecular determinants of virulence...
  12. doi request reprint Assessment of hepatitis C virus protein sequences with regard to interferon/ribavirin combination therapy response in patients with HCV genotype 1b
    Sanja Glisic
    Centre for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, Belgrade, Serbia
    Protein J 31:129-36. 2012
    ..On the basis of these results, a simple bioinformatics criterion that could be useful in assessment of the response of HCV-infected patients to the combination therapy has been proposed...
  13. ncbi request reprint Safety and ethical consideration of AIDS vaccine
    Veljko Veljkovic
    Center for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, Belgrade, Yugoslavia
    Int Rev Immunol 23:465-86. 2004
    ..This situation opens a serious question about the safety of vectored AIDS vaccine and the ethics of their trials in humans...
  14. ncbi request reprint Application of VIP/NTM-reactive natural antibodies in therapy of HIV disease
    Veljko Veljkovic
    Center for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, Belgrade, Yugoslavia
    Int Rev Immunol 23:437-45. 2004
    ..These findings point out the VIP/C2-reactive natural antibodies as an important agent for immunotherapy of HIV disease...
  15. ncbi request reprint Molecular makeup of HIV-1 envelope protein
    Veljko Veljkovic
    Center for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, Belgrade, Yugoslavia
    Int Rev Immunol 23:383-411. 2004
    ..Here we described some of these properties of HIV-1 gp120 that represent the main obstacle in the development of effective and safe AIDS vaccine...
  16. ncbi request reprint AIDS vaccine: state of the art at the beginning of the third millennium
    Veljko Veljkovic
    Center for Multidisciplinary Reserarch, Institute of Nuclear Sciences Vinca, Belgrade, Yugoslavia
    Int Rev Immunol 23:369-81. 2004
    ..We also give a brief overview of the state of the art in development of AIDS vaccines together with a short summary of the supporting data and obstacles in this development...
  17. ncbi request reprint Anti-IgG antibodies from sera of healthy individuals neutralize HIV-1 primary isolates
    Radmila Metlas
    Centre for Multidisciplinary Research, Institute of Nuclear Science Vinca, Belgrade, Serbia
    Curr HIV Res 5:261-5. 2007
    ..Since, hallmark of HIV-1 infection are immunological disorders we hypothesizes that they might be corrected to some extend by anti-IgG antibodies...
  18. ncbi request reprint Simple criterion for selection of flavonoid compounds with anti-HIV activity
    Veljko Veljkovic
    Centre for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, PO Box 522, 11001 Belgrade, Serbia
    Bioorg Med Chem Lett 17:1226-32. 2007
    ....
  19. ncbi request reprint AIDSVAX results: an important open question
    Veljko Veljkovic
    Center for Multidisciplinary Research, Institute of Nuclear Sciences Vinca, P O Box 522, 11001 Belgrade, Yugoslavia
    Vaccine 21:3528-9. 2003
    ..Results of the recently finished clinical trial of AIDSVAX represent a good base for this important analysis...